Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Total Liabilities (2024 - 2025)

Historic Total Liabilities for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $141.8 million.

  • Xilio Therapeutics' Total Liabilities rose 16411.78% to $141.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.8 million, marking a year-over-year increase of 16411.78%. This contributed to the annual value of $53.5 million for FY2024, which is N/A changed from last year.
  • Xilio Therapeutics' Total Liabilities amounted to $141.8 million in Q3 2025, which was up 16411.78% from $126.7 million recorded in Q2 2025.
  • Over the past 5 years, Xilio Therapeutics' Total Liabilities peaked at $141.8 million during Q3 2025, and registered a low of $53.5 million during Q4 2024.